The use of the classic immunization-transplantation technique has established that tumor-specific immune responses can be generated that can neutralize subsequently implanted syngeneic tumor cells (1-3). However, the importance of such responses in influencing the appearance of primary tumors is much less clear.
The use of the classic immunization-transplantation technique has established that tumor-specific immune responses can be generated that can neutralize subsequently implanted syngeneic tumor cells (1) (2) (3) . However, the importance of such responses in influencing the appearance of primary tumors is much less clear.
Murine Rous sarcoma is a useful model to investigate this question. These tumors are induced by neonatal inoculation of RCTM, are of murine origin [i.e., they have the murine karyotype (4)], bear crossreacting TST A (5), and do not release infectious virus because the replication of RSV in murine cells is defective (6) . We have previously shown that H-2 congenic strains of mice differ in susceptibility to primary tumor induction (7) , that an H-2 linked gene(s) exerts a major influence on Rous sarcoma incidence, and that ability to mount a tumor-neutralizing immune response is inversely correlated with susceptibility (8) . In addition, we found that susceptibility to tumor induction declined rapidly in all strains during the first 4 days of life (7) . Other investigators (9) , using the one-stage leukocyte adherence inhibition assay, detected significant specific cellular reactivity to Rous sarcoma antigen extracts with responder cells from mice bearing or immunized against primary or transplanted Rous sarcomas.
The present studies were undertaken to test the influence on primary Rous sarcomagenesis of compromising or augmenting the antitumor immune response early in the latency period. This goal was approached by 1) prolonged immunosuppression with heterologous ATS beginning on day 7 or 21 of life and by 2) inoculation of the neonatally RSV-infected mice with various populations of syngeneic adult lymphoid cells at the same time that they received oncogenic insult or were 7 days of age. Using the inoculation model, we also demonstrated that a difference exists between the antitumor immune response of mice that develop primary Rous sarcomas and the response of RCTM-inoculated genetically identical littermates that do not develop them. We also showed that immunologic status of the mother can radically increase or decrease the incidence of primary Rous sarcoma in her offspring.
MATERIALS AND METHODS
Mice.-The following strains of mice were bred and maintained in our colony: C57BL/IOScSn (BIO), AlWySn (A), and [BIO.C(47N) X A.BY]Fl offspring (H_2 bb ). The origin and maintenance of these mice have been previously described (7, 10) .
Virus.-The Schmidt-Ruppin strain (subgroup D) of RSV used in these experiments was provided by Dr. D. P. Bolognesi, Department of Surgery, Duke University, Durham, North Carolina. The isolation of this strain has been described elsewhere (11) .
Production of primary murine Rous sarcoma.-The procedure for the induction of primary murine Rous sarcomas has been detailed previously (7) . Neonatal mice «24 hr old) were given im and sc injections in the left rear legs. Each injection consisted of 0.025 ml of a suspension of tumor cells and small fragments produced by mincing of RSV -induced chicken sarcomas in Waymouth's medium MB 752/1 with 10% FBS (KC Biologicals, Lenexa, Kans.). The tumor was then dispersed by a brief pulse (5-10 sec) in a VirTis tissue homogenizer (VirTis Co. Inc., Gardiner, N.Y.). The suspension was diluted to 13% in dimethyl sulfoxide (Fisher Scientific Co., Fair Lawn, N.].) by dropwise addition on ice, frozen slowly in small aliquots to -70° C, and stored in liquid nitrogen.
Mice were observed twice weekly and inspected for palpable tumors at 20-250 days of age. Comparisons of tumor incidence between groups were made by 2X2 contingency table chi-square testing. Mice that had received RCTM as newborns but had not developed tumors by 200 days of age were designated VT-.
Preparation of heterologous ATS.-ATS was prepared as previously described (12) with the following modification: A goat was immunized sc in 10 sites with 1010 murine thymocytes in 5 ml PBS emulsified with an equal volume of Freund's complete adjuvant; 21 and 23 days later the goat was given an sc booster of 7XI0 9 thymocytes in 10 ml PBS. The goat was bled 10 days later from the jugular vein and the serum was collected, heat inactivated at 56° C for 30 minutes, absorbed with packed mouse erythrocytes (l :20, voll vol), aliquoted, and stored at -70° C. The immunosuppressi ve potency of the A TS in mice was determined as previously described (12) . The efficiency of the ATS was assayed in mice given weekly treatments of ATS and challenged with an H-2 incompatible RSV-induced transplanted tumor. All ATS used in this study at least doubled the survival times of the tumor grafts.
Immunization of mice.-A primary murine Rous sarcoma arising in an A strain mouse was established JNCI. VOL. !J3. NO. 6, DECEMBER 1979 in transplantation as previously described (9) . BIO mice were immunized against allogeneic A Rous tumor by trocar implantation six times at 2-week intervals (text- fig. 2, table 3 ). The alloimmunized mice were challenged with ten times the median lethal dose of syngeneic Rous sarcoma cells 2 weeks after the last immunization. Only the mice that remained tumor-free were used as immune donors.
For the maternal transfer experiment (text- fig. 3 ), BIO female mice were immunized at 2-week intervals with 4 different primary allogeneic Rous sarcomas and bled 7 days after the last immunization; the sera were pooled. These mice were mated to A strain males 5 days later.
Preparation of lymphoid cells.-Lymphoid cells to be used in adoptive transfer experiments were obtained from the spleen and lymph nodes (pooled from axillary, inguinal, and mesenteric nodes) of the appropriate donor. Single-cell suspensions were prepared from the spleens or lymph nodes of 3 or more donors. The cell suspensions were washed twice and then resuspended to a final concentration of 6X10 7 cells/ml in PBS (pH 7.2, 0.01 M phosphate). Cell viability was always greater than 90% as determined by trypan blue exclusion. All newborn mice used as recipients in cell transfer studies received ip 0.05 ml of the appropriate cells.
Lymphocyte stimulation.-The one-way MLTR was performed as described by Senik et al. (13) with minor modifications. Single-cell suspensions were prepared from the spleens or lymph nodes (pooled from inguinal, axillary, and mesenteric nodes) of 3 or more donors. The cells were washed three times and resuspended in RPMI-1640 (GIBCO, Grand Island, N.Y.) containing 10% heat-inactivated FBS, 50 p,g gentamycin/ml (Schering Corp., Kenilworth, N.].), and 5XIO-5 M 2-mercaptoethanol (Fisher Scientific Co.). Tumor cells were obtained from a BIO Rous sarcoma cell line maintained in cell culture as previously described (9) . Tumor cells were incubated at 37° C for 30 minutes in 3 ml tissue culture medium (2X10 6 cells/ml) containing 25 p,g mitomycin C/ml (Sigma Chemical Co., St. Louis, Mo.), washed three times, and resuspended to the appropriate cell concentration in tissue culture medium. All cultures, consisting of 0.1 ml of the stimulating cell suspension (2X10 6 cells/ml) and 0.1 ml of the responder cell suspension (2X10 6 cells/ml), were established in triplicate in flat-bottom Microtiter plates (Falcon Plastics, Oxnard, CaliL). Cultures were incubated for 48 or 72 hours in a humidified 5% CO2 -air atmosphere at 37° C. After the incubation period, 1.0 Ci of tritiated thymidine (Schwarz/Mann Div., Becton, Dickinson & Co., Orangeburg, N.].; sp act, 50 Ci/mmole) was added to each well, and the cultures were incubated for an additional 4 hours. The cultures were then precipitated onto Whatman glass fiber filters with the use of an automated multiplesample cell harvester (Otto Hiller Co., Madison, Wis.). The filters were dried and the amount of label incorporated was determined by liquid scintillation count-ing. The RI was calculated by means of the following formula, as described by Vanky and Stjernsward (14) Similar experiments were performed with the use of chicken fibroblasts instead of Rous sarcoma cells as stimulators. The significance of the isotope ~ptake (expressed as cpm) of the test samples was compared to that of the control samples by Student's t-test (15) .
RESULTS
To determine if suppression of the immune response affected the development of primary Rous sarcomas, mice were given RCTM at birth followed by weekly injections of ATS. They received 0.05 ml ATS the first and second weeks, 0.1 ml the third week, and 0. mice were being eliminated or held in check by the immune response.
In a different approach to investigate the role of the immune response during oncogenesis, an experiment was conducted in which ATS treatment was begun at the time that sarcomas normally start to appear. The effect of immunosuppression on Rous sarcoma incidence was examined in [BlO.C(47N) X A.BY]FJ mice that were inoculated with RCTM during the first 24 hours of life and treated with ATS beginning 21 days after birth. Mice in the experimental group displayed a modestly lower tumor incidence and prolonged tumor latency periods for almost the entire first half of the 250-day observation period (text- fig. IB ). The mean tumor latency periods of 64.5 and 79.9 days observed at day 100 in control and experimental groups, respectively, differed significantly (P<0.05). During the second half of the observation period, however, more primary Rous sarcomas developed in the immunosuppressed group. By the end of the study, the tumor incidence in ATS recipients significantly exceeded (P<0.05) that in control animals (text- fig. IB ).
This finding led us to test whether the remaining tumors could be prevented from appearing by specific augmentation of the antitumor immune response. This approach was tested by inoculation of neonatal mice, at the same time as challenge with RCTM, with 3XI0 6 lymphoid cells from syngeneic adult animals rendered demonstrably immune to syngeneic turn or transplantation by immunization with allogeneic Rous sarcoma. The oncogenic agent was administered im, and the lymphoid cells were given ip. Only a modest degree of protection resulted from this treatment (text- fig. 2A ). The treated mice, whether recipients of LNC or SC, displayed about a 2-week delay in the appearance of tumors, but beyond 50 days the incidence curves of treated and control mice were essentially parallel. Thus this treatment prevented the emergence of only a relatively small, but statistically significant, number of early arising tumors.
To test whether lymphoid cells from VT-mice, which had previously been shown to be resistant to challenge with syngeneic tumor (8), could protect neonatal mice against primary oncogenesis and to determine whether they differed in this respect from tumor-bearing littermates, an experiment similar to that described above was undertaken. BlO mice were inoculated within 24 hours of birth with RCTM and simultaneously with 3X106 lymphoid cells from adult total incidence. This finding was true also for SC from normal syngeneic adults, whereas normal LNC caused no such delay and resulted in a slight but statistically insignificant increase in total tumor incidence (text- fig.  2D ). RSV -infected newborns that received either SC or LNC from VT-donors on day 7 had consistently more tumors than did the untreated control group (text- fig.  2F ). Statistical analysis, however, did not reveal the tumor incidence in the treated groups to be significantly different (P>0.05) from that in the control group. The transfer of SC or LNC from T+ donors on day 7 appeared to have little or no effect on tumor incidence (text- fig. 2G ). Of the BIO newborns that received lymphoid cells from deliberately immunized donors, 2 groups showed varying results. Tumor incidence was significantly enhanced (P<0.005) when LNC were transferred from deliberately immunized donors to Rous-infected newborn recipients on day 7; however, no enhancement was observed in the recipients of SC from these same donors (text- fig. 2E ). The tumor incidence (71%) in these SC recipients closely resembled the incidence observed in the control group. The transfer of normal SC or LNC from adult BIO donors to other groups of syngeneic, virus-infected recipients on day 7 also resulted in increased tumor frequencies. A pattern of marked stimulation (text- fig. 2H ) was readily apparent in this experiment despite the smaller number of animals in the treated groups. We also observed the tumor-stimulatory effect of normal adult lymphoid cells given on day 7 in the genetically resistant H-2 congenic strain BIO.D2 (table   2) .
In addition, we tested the effect of transfer of serum from syngeneic immune, VT-, or T+ mice on days 1 and 7 after birth on the incidence of primary Rous tumors. The results of these experiments are shown in table 3. All three sera reduced the incidence of Rous sarcoma, though only the effect of T+ serum was statistically significant (P<0.005).
In an attempt to measure the influence of maternal immune status on the primary tumor susceptibility of neonatal mice, we divided 140 young adult (2 to 4 mo old) female BIO mice into 3 groups. The first group was immunized over 59 days with sc injections of pieces of 4 different allogeneic primary Rous sarcomas. After the third and fourth immunizations, the immune females were bled and the sera were collected and frozen without heat inactivation. All females were then mated to experienced 5-to 9-month-old A strain males. On days 2, 9, and 16 after mating, all females in the second group were given ip injections of 0.2 ml undiluted serum from the immunized females. A third group was left untreated. At birth all FI progeny were inoculated with RCTM and returned to their mothers. The progeny were weaned and separated by sex at 30 days of age. All mothers were isolated from late pregnancy until weaning; thus all mice suckled on their biologic mothers. Both BIO and A mice are relatively susceptible to primary Rous sarcoma, and the FI offspring are also known to be susceptible (Whitmore AC: Unpublished observations). There were 110 mice in the group with actively immunized mothers, 31 offspring of passively immunized mothers, and 127 normal controls. Tumor incidence in each group is shown in text-figure 3. Offspring of immune mothers were significantly less susceptible (P<0.025) to primary Rous oncogenesis than were the offspring of control mothers, whereas offspring of serum-treated females were significantly more susceptible (P<0.025) than was the control group. No significant difference between mean latency period or range of latency periods was noted between the control group and either experimental group. ML TR were performed to determine if the lymphoid cells from tumor-bearing animals were tolerant to the tumor cells, thus accounting for the differential effect observed between lymphoid cells from V+T-and T+ hosts used in the newborn transfer studies. SC from tumor-bearing animals responded as well as SC from V+T-animals at 48 and 72 hours (table 4) .
.---------I
To ensure that the protection observed in animals receiving V+T-cells was not simply caused by the recognition and destruction of chicken antigens on RCTM, lymphoid cells from V+T-, T+, and normal animals were cultured with normal chicken fibroblasts. The results indicate that lymphoid cells from V+T-(groups A, B) or tumor-bearing (groups C, D) animals demonstrated no greater reactivity to normal chicken fibroblasts than did lymphoid cells from normal animals (groups E, F; table 5). The mice in groups G and H were positive controls immunized with RCTM as adults.
DISCUSSION
These studies were motivated by a simple, fundamental observation made early in the genetic studies to which we first applied the murine Rous sarcoma system (7) . With reasonably large sample sizes, no susceptible strain has 100% tumor incidence, and no resistant strain is absolutely resistant. This observation eliminated a few possibly trivial explanations for the strain-specific differences in primary tumor incidence such as all-or-none differences in cell susceptibility to transformation or ability to perform any tumor surveillance function. Our hypothesis (8) that H-2-linked differences in susceptibility to prImary Rous oncogenesis are due to differences in ability to mount an effective tumor-rejection immune response to the TST A of murine Rous sarcomas led us to suggest that we should be able to alter in a predictable direction the incidence of primary Rous tumors in any strain by specific augmentation or inhibition of that anti-Rous immune response. These studies were undertaken to test that hypothesis.
Our observation that tumor incidence can be increased by prolonged immunosuppression with ATS agrees with considerable evidence [reviewed in (16) ] that the. incidence of tumors induced in rodents by oncogenic viruses is increased by treatments that impair the generation of T-cell-rriediated immunity. However, these treatments have little or no effect on the incidence of tumors induced by carcinogenic chemicals or foreign bodies (17) and tumors arising spontaneously. We also made the unexpected observation that ATS treatment beginning on day 21 after RCTM injection increased tumor incidence but radically delayed the mean time of tumor appearance. Tumors occurred in both control groups mainly during the first 100-150 days of life, and tumor incidence had leveled off by 200 days. In both ATS-treated groups, tumor incidence curves were almost linear until the termination of observation at 250 days. The results support two conclusions: 1) In normal, genetically susceptible mice inoculated at birth with RCTM, the emergence of long-latency primary tumors is held in check by some ATS-sensitive function(s) perhaps mediated by circulating thymus-dependent lymphocytes (18) . 2) Between 7 and 21 days of life, some ATS-sensitive function(s) is involved in stimulating or hastening the appearance of a proportion of early arising primary Rous tumors. We do not know whether the same function is involved in both effects, but if an antitumor immune response is found to be the function suppressed by ATS treatment between 7 and 21 days of life, these data constitute direct confirmation of Prehn's prediction (19) that an immune response may stimulate or inhibit tumor growth at different times or with different degrees of expression of that response.
Text- figure 2 shows the tumor incidence in 1,135 BIO mice (H_2 b ) inoculated ip with various populations of normal or specifically sensitized adult lymphoid cells either simultaneously with RCTM injection (day 1) or 1 week later (day 7). When 3XI0 6 adult lymphoid cells are transferred into syngeneic recipient mice on day 1, only SC or LNC from V+T-mice (those inoculated at birth with RCTM but which did not develop primary Rous sarcoma by 200 days of age) significantly reduced tumor incidence. That normal or T+ adult lymphoid cells administered at birth will not change the ultimate tumor incidence is not surprising, but why lymphoid cells from syngeneic mice rendered demonstrably immune to syngeneic Rous tumor transplantation provide such weak protection from primary oncogenesis is still unclear.
The obvious difference between deliberately immunized mice and V+T-mice is that V+T-mice have, at some time in their lives, been exposed to and rejected chicken sarcoma cells bearing chicken species-specific antigens. The protective effect of V+T-lymphoid cells on day 1 might then be due mainly to elimination of RCTM; thus the severity of the oncogenic insult may be effectively reduced. We have shown that neither V+T-nor T+ mice demonstrate a secondary T-lymphocyte proliferative response against chicken antigens, whereas lymphocytes from positive controls immunized as adults with RCTM showed significant secondary response. However, our results with the MLTR also indicate that proliferation of primed T-lymphocytes in vitro may not always correlate with the ability to protect newborn mice from primary Rous oncogenesis. Both SC and LNC from V+T-adults will protect newborn syngeneic mice in vivo, but only SC will incorporate tritiated thymidine in response to murine Rous sarcoma cells in vitro. T+ SC will also respond to Rous tumor antigens in vitro but will confer no protection in vivo. Secondary in vitro proliferation assays perhaps quantitate mainly Lyl + memory cells (20) , but tumor protection in neonatal mice may be a function of Ly23+ effector T-cells or any other cell type or stage of development found in both spleens and lymph nodes of V+T-animals.
When SC or LNC from the same 4 groups of adult mice were transferred into syngeneic mice given injections of RCTM on day 7, a different pattern of effects on tumor incidence was seen. No lymphoid cell population reduced the incidence of primary Rous sarcoma; however, SC and LNC from normal adults and LNC from immunized donors increased tumor incidence. The ability of normal SC or LNC to increase tumor incidence when administered on day 7 was also seen in the genetically resistant strain BlO.D2 (H_2
The results of the adult lymphoid cell transfers therefore only partially confirm our simplistic initial prediction that tumor incidence should be susceptible to reduction by transfer of specifically sensitized adult lymphoid cells into neonatal mice inoculated with RCTM. Reduction of tumor incidence by the administration of V+T-lymphoid cells on day I is possible, but by day 7 no sensitized lymphoid cell population can reduce tumor incidence, perhaps because of the tumorstimulating activity of some component of normal lymphoid cells administered at that time. Also, some early event in murine Rous oncogenesis may occur between I and 7 days of age to make the nascent tumor cell (or cells) insensitive to any antitumor immune response. This is the period in which transitory chicken sarcoma growth occurs in the suckling mouse, after which chicken tumors completely regress (21) . One might propose that the event that renders the growing tumor insensitive to elimination by immunologic effectors from adult, sensitized animals is the transformation of mouse fibroblasts by infection with free virus or by fusion with transformed, virus-infected chicken cells. The critical period for immunologic intervention is, at any rate, very early in the process of murine Rous oncogenesis.
Cell separations are now being performed that will test whether the tumor-inhibitory activity of V+T-cells on day I or the tumor-stimulatory activity of normal cells on day 7 can be removed by treatment with antimouse immunoglobulin serum plus complement, rabbit antimouse brain serum plus complement, or carbonyl iron and magnet.
We found that the transfer of serum from deliberately immunized, V+T-, and T+ mice on days I and 7 of life reduced the incidence of primary Rous sarcoma. The interesting observation is that serum from the tumor bearer was most effective in reduction of primary tumor incidence. We have not studied the humoral immune response of mice to primary Rous sarcoma and have no explanation for the pronounced antitumor effect of serum from mice that have apparently lost whatever immune surveillance battle the hosts might once have waged. However, there may be some relation to the observations of Jonsson and Sjogren (22) , who found virus-neutralizing antibodies in the sera of both V+T-and primary tumor-bearing adult mice inoculated with RCTM as newborns. Sera from tumor bearers should be subjected to fractionation to determine if the antitumor activity is immunglobulin in nature. At that time, various immunologic methods can be applied to defining the specificity of the relevant antibodies.
We were impressed with the great sensitivity of Rous tumor incidence to specific immunologic intervention in the first few days after birth, and because we were aware that pregnant rodents can apparently transfer both immunocompetent lymphoid cells and some immunoglobulin classes to their progeny before and after parturition [i.e., across the placenta and in colostrum and milk (23)], we contrived to test the influence of a demonstrable state of maternal immunity to syngeneic Rous tumor challenge. The offspring of immune mothers are less susceptible to primary oncogenesis than are offspring of control mothers. Another group of mothers was treated with pooled serum from the immune mothers on days 2, 9, and 16 after experienced A strain males were introduced into the breeding pens. The offspring of these passively immunized females were significantly more susceptible to primary Rous oncogenesis than were untreated control mice. We do not know enough about either this phenomenon or the decrease in primary tumor incidence caused by T+ serum to profitably discuss their obvious differences. Reciprocal foster-nursing experiments should be performed to define the relative importance of preparturition and postparturition events in the transfer of tumor resistance from immunized mothers.
We wish to emphasize that the studies outlined here are not precisely analogous to studies showing effects of syngeneic lymphocytes or serum on the number of cells necessary for successful transplantation of a longestablished transplanted turn or line. The authors simply lack the encyclopedic knowledge to encompass all the experimental data on this subject and the acumen needed to draw conclusions about primary tumor formation and growth from experiments conducted with transplanted tumor cell lines. These cell lines have been adapted, often by years of passage in marginally immunosuppressed syngeneic recipients, to kill all recipients within a convenient period of time. Many transplanted cell lines have also been selected for other features not necessarily relevant to primary oncogenesis, such as the ease with which single-cell suspensions can be prepared and the susceptibility to T-cell-mediated cytolysis. However, a few good studies (24-32) have been done on the effect of immune intervention in two other systems of primary murine oncogenesis.
If M-MuSV is administered to young «3 wk old) BALBI c mice, the incidence of primary tumors is very high, and the tumors all grow progressively to kill the host. If the M-MuSV is injected after 3 weeks, a large proportion of the primary sarcomas regresses within 3 or 4 more weeks. This regression is thought to be immunologic (24) . Fefer (25) showed that if lymphoid cells from adult animals whose M-MuSV-induced tu-· mors have regressed are given to tumor-bearing BALB/c mice inoculated with M-MuSV at 3 weeks of age, the proportion of tumors eventually regressing increases from 4 to 37%. Gorczynski (26) showed that the increase in regression frequency is mediated by a Thy I-bearing lymphocyte. Sera from immune mice also increase the number of regressions (25) .
Two other groups have developed effective vaccination procedures for reduction of the incidence of primary Mu LV-associated neoplasms by active (27) (28) (29) or passive (27, 28, 30, 31) immunization with Gross MuLV and M-MuSV pseudotypes (32), Rauscher MuLV (28), radiation-induced MuLV (29), or Friend MuLV (31) . A common feature of these studies is the observation that immunization must be started very early in life (for mice receiving the oncogenic MuLV by the germ-line route) or before or very early in oncogenesis for mice receiving an external oncogenic agent. Apparently, MuLV -induced tumors are most susceptible to the primary tumor incidence-decreasing effects of antiviral immunity before or immediately after the susceptible target cell or tissue is transformed by the oncogen.
Our findings have two simple implications for those who would design rational specific immunotherapeutic procedures for solid neoplasms: I) Immunotherapy of murine Rous sarcomas must be started early in the process of oncogenesis to significantly reduce the ultimate tumor incidence (i.e., immunoprevention is more effective than immunotherapy).
2) The transfer of unseparated adult lymphoid cell populations into young syngeneic mice increases ultimate tumor incidence. This tumor-promoting activity of normal lymphoid cells may mask weaker antitumor effects of sensitized cells in some intervention protocols.
